Alphaviruses present serious health threats as emerging and re-emerging viruses. Venezuelan equine encephalitis virus (VEEV), a New World alphavirus, can cause encephalitis in humans and horses, but there are no therapeutics for treatment. To date, compounds reported as anti-VEEV or anti-alphavirus inhibitors have shown moderate activity. To discover new classes of anti-VEEV inhibitors with novel viral targets, we used a high-throughput screen based on the measurement of cell protection from live VEEV TC-83-induced cytopathic effect to screen a 340,000 compound library. Of those, we identified five novel anti-VEEV compounds and chose a quinazolinone compound, CID15997213 (IC50 = 0.84 μM), for further characterization. The antiviral effect of CID15997213 was alphavirus-specific, inhibiting VEEV and Western equine encephalitis virus, but not Eastern equine encephalitis virus. In vitro assays confirmed inhibition of viral RNA, protein, and progeny synthesis. No antiviral activity was detected against a select group of RNA viruses. We found mutations conferring the resistance to the compound in the N-terminal domain of nsP2 and confirmed the target residues using a reverse genetic approach. Time of addition studies showed that the compound inhibits the middle stage of replication when viral genome replication is most active. In mice, the compound showed complete protection from lethal VEEV disease at 50 mg/kg/day. Collectively, these results reveal a potent anti-VEEV compound that uniquely targets the viral nsP2 N-terminal domain. While the function of nsP2 has yet to be characterized, our studies suggest that the protein might play a critical role in viral replication, and further, may represent an innovative opportunity to develop therapeutic interventions for alphavirus infection.
References
[1]
Weaver SC, Barrett AD (2004) Transmission cycles, host range, evolution and emergence of arboviral disease. Nature reviews Microbiology 10: 789–801 doi:1038/nrmicro1006.
[2]
Aguilar PV, Estrada-Franco JG, Navarro-Lopez R, Ferro C, Haddow AD, et al. (2011) Endemic Venezuelan equine encephalitis in the Americas: hidden under the dengue umbrella. Future Virol 6: 721–740. doi: 10.2217/fvl.11.50
Fine DL, Jenkins E, Martin SS, Glass P, Parker MD, et al. (2010) A multisystem approach for development and evaluation of inactivated vaccines for Venezuelan equine encephalitis virus (VEEV). J Virol Methods 163: 424–432. doi: 10.1016/j.jviromet.2009.11.006
[5]
Berge TO, Banks IS, Tigertt WD (1961) Attenuation of venezuelan equine encephalomyelitis virus by in vitro cultivation in guinea-pig heart cells. Am J Epidemiol 73: 209–218.
[6]
Pittman PR, Makuch RS, Mangiafico JA, Cannon TL, Gibbs PH, et al. (1996) Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. Vaccine 14: 337–343. doi: 10.1016/0264-410x(95)00168-z
[7]
Jahrling PB, Stephenson EH (1984) Protective efficacies of live attenuated and formaldehyde-inactivated Venezuelan equine encephalitis virus vaccines against aerosol challenge in hamsters. J Clin Microbiol 19: 429–431.
[8]
Pratt WD, Gibbs P, Louise M, Pitt M, Schmaljohn AL (1998) Use of telemetry to assess vaccine induced protection against parenteral and aerosol infections of Venezuelan equine encephalitis virus in non-human primates. Vaccine 16: 1056–1064. doi: 10.1016/s0264-410x(97)00192-8
[9]
Markland W, McQuaid TJ, Jain J, Kwong AD (2000) Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrobial Agents and Chemotherapy 44: 859–866. doi: 10.1128/aac.44.4.859-866.2000
[10]
Julander JG, Bowen RA, Rao JR, Day C, Shafer K, et al. (2008) Treatment of Venezuelan equine encephalitis virus infection with (？)-carbodine. Antiviral Res 80: 309–315. doi: 10.1016/j.antiviral.2008.07.002
[11]
Selvam P, Vijayalakshimi P, Smee DF, Gowen BB, Julander JG, et al. (2007) Novel 3-sulphonamido-quinazolin-4(3H)-one derivatives: microwave-assisted synthesis and evaluation of antiviral activities against respiratory and biodefense viruses. Antivir Chem Chemother 18: 301–305.
[12]
Kehn-Hall K, Narayanan A, Lundberg L, Sampey G, Pinkham C, et al. (2012) Modulation of GSK-3beta activity in Venezuelan equine encephalitis virus infection. PLoS One 7: e34761. doi: 10.1371/journal.pone.0034761
[13]
Fine DL, Roberts BA, Teehee ML, Terpening SJ, Kelly CL, et al. (2007) Venezuelan equine encephalitis virus vaccine candidate (V3526) safety, immunogenicity and efficacy in horses. Vaccine 10.1016/j.vaccine.2006.10.030 1868–1876. doi: 10.1016/j.vaccine.2006.10.030
[14]
Pratt WD, Davis NL, Johnston RE, Smith JF (2003) Genetically engineered, live attenuated vaccines for Venezuelan equine encephalitis: testing in animal models. Vaccine 21: 3854–3862. doi: 10.1016/s0264-410x(03)00328-1
[15]
Pauwels R, Andries K, Desmyter J, Schols D, Kukla MJ, et al. (1990) Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 343: 470–474. doi: 10.1038/343470a0
[16]
Julander JG, Skirpstunas R, Siddharthan V, Shafer K, Hoopes JD, et al. (2008) C3H/HeN mouse model for the evaluation of antiviral agents for the treatment of Venezuelan equine encephalitis virus infection. Antiviral Res 78: 230–241. doi: 10.1016/j.antiviral.2008.01.007
[17]
Sawicki DL, Sawicki SG (1980) Short-lived minus-strand polymerase for Semliki Forest virus. Journal of Virology 34: 108–118.
[18]
Hardy FM (1959) The growth of Venezuelan equine encephalomyelitis virus in various tissue cultures. Am J Hyg 70: 21–27.
[19]
Scherer WF, Ellsworth CA, Ventura AK (1971) Studies of viral virulence. II. Growth and adsorption curves of virulent and attenuated strains of Venezuelan encephalitis virus in cultured cells. Am J Pathol 62: 211–219.
[20]
Gomez de Cedron M, Ehsani N, Mikkola ML, Garcia JA, Kaariainen L (1999) RNA helicase activity of Semliki Forest virus replicase protein NSP2. FEBS Lett 448: 19–22. doi: 10.1016/s0014-5793(99)00321-x
[21]
Rikkonen M, Peranen J, Kaariainen L (1994) ATPase and GTPase activities associated with Semliki Forest virus nonstructural protein nsP2. J Virol 68: 5804–5810. doi: 10.1016/0042-6822(92)90570-f
[22]
Gorbalenya AE, Koonin EV (1993) Helicases - Amino-Acid-Sequence Comparisons and Structure-Function-Relationships. Current Opinion in Structural Biology 3: 419–429. doi: 10.1016/s0959-440x(05)80116-2
[23]
Lulla V, Merits A, Sarin P, Kaariainen L, Keranen S, et al. (2006) Identification of mutations causing temperature-sensitive defects in Semliki Forest virus RNA synthesis. Journal of Virology 80: 3108–3111. doi: 10.1128/jvi.80.6.3108-3111.2006
[24]
Hardy WR, Hahn YS, de Groot RJ, Strauss EG, Strauss JH (1990) Synthesis and processing of the nonstructural polyproteins of several temperature-sensitive mutants of Sindbis virus. Virology 177: 199–208. doi: 10.1016/0042-6822(90)90473-5
[25]
Russo AT, White MA, Watowich SJ (2006) The crystal structure of the Venezuelan equine encephalitis alphavirus nsP2 protease. Structure 14: 1449–1458. doi: 10.1016/j.str.2006.07.010
[26]
Zhang D, Tozser J, Waugh DS (2009) Molecular cloning, overproduction, purification and biochemical characterization of the p39 nsp2 protease domains encoded by three alphaviruses. Protein expression and purification 64: 89–97. doi: 10.1016/j.pep.2008.10.013
[27]
Sawicki DL, Perri S, Polo JM, Sawicki SG (2006) Role for nsP2 proteins in the cessation of alphavirus minus-strand synthesis by host cells. J Virol 80: 360–371. doi: 10.1128/jvi.80.1.360-371.2006
[28]
Akhrymuk I, Kulemzin SV, Frolova EI (2012) Evasion of the innate immune response: the Old World alphavirus nsP2 protein induces rapid degradation of Rpb1, a catalytic subunit of RNA polymerase II. J Virol 86: 7180–7191. doi: 10.1128/jvi.00541-12
[29]
Kehn-Hall K, Narayanan A, Lundberg L, Sampey G, Pinkham C, et al. (2012) Modulation of GSK-3beta activity in Venezuelan equine encephalitis virus infection. PLoS One 10.1371/journal.pone.0034761 e34761. doi: 10.1371/journal.pone.0034761
[30]
Huggins JW, Jahrling PB, Rill W, Linden CD (1983) Characterization of the binding of the TC-83 strain of Venezuelan Equine encephalomyelitis virus to BW-J-M, a mouse macrophage-like cell line. J Gen Virol 64(Pt 1): 149–157. doi: 10.1099/0022-1317-64-1-149
[31]
Bernard KA, Klimstra WB, Johnston RE (2000) Mutations in the E2 glycoprotein of Venezuelan equine encephalitis virus confer heparan sulfate interaction, low morbidity, and rapid clearance from blood of mice. Virology 276: 93–103. doi: 10.1006/viro.2000.0546
[32]
Chung DH, Jonsson CB, Maddox C, McKellip SN, Moore BP, et al. (2010) HTS-driven discovery of new chemotypes with West Nile Virus inhibitory activity. Molecules 15: 1690–1704. doi: 10.3390/molecules15031690
[33]
Zhang JH, Chung TD, Oldenburg KR (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomolecular Screening 67–73. doi: 10.1177/108705719900400206
[34]
Dower K, Rubins KH, Hensley LE, Connor JH (2011) Development of Vaccinia reporter viruses for rapid, high content analysis of viral function at all stages of gene expression. Antiviral Res 91: 72–80. doi: 10.1016/j.antiviral.2011.04.014
[35]
Whitlow ZW, Connor JH, Lyles DS (2006) Preferential translation of vesicular stomatitis virus mRNAs is conferred by transcription from the viral genome. J Virol 80: 11733–11742. doi: 10.1128/jvi.00971-06
[36]
Chung DH, Moore BP, Matharu DS, Golden JE, Maddox C, et al. (2013) A cell based high-throughput screening approach for the discovery of new inhibitors of respiratory syncytial virus. Virol J 10: 19. doi: 10.1186/1743-422x-10-19
[37]
Gupta CK, Leszczynski J, Gupta RK, Siber GR (1996) Stabilization of respiratory syncytial virus (RSV) against thermal inactivation and freeze-thaw cycles for development and control of RSV vaccines and immune globulin. Vaccine 14: 1417–1420. doi: 10.1016/s0264-410x(96)00096-5
